Literature DB >> 7963555

Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules.

C V Harding1, R Song.   

Abstract

Exogenous Ags that are processed in vacuolar endocytic compartments are generally presented by class II MHC molecules and not class I MHC (MHC-I) molecules, which conventionally present cytoplasmic or endogenous Ags. Accordingly, i.v. immunization of C57BL/6 mice with soluble OVA did not elicit a CD8 T cell response. However, i.v. immunization with OVA coupled to Latex particles (Latex-OVA) elicited an OVA-specific CD8 T cell response in vivo (particles from 59 to 2000 nm diameter were effective). In vitro, Latex-OVA was processed by H-2b macrophages and presented by Kb at least 100- to 1000-fold more efficiently than was soluble OVA. Inhibition of phagocytosis by cytochalasin D blocked the processing of Latex-OVA, whereas processing was not blocked by Brefeldin A. Latex-OVA was presented directly by H-2b macrophages or after "regurgitation" of processed OVA peptide from viable MHC-disparate macrophages for binding to surface Kb molecules on fixed H-2b macrophages. Peptide regurgitation was observed during processing of both Latex-OVA and Salmonella typhimurium 14028s that express an OVA fusion protein (Crl-OVA). However, the regurgitation pathway was less efficient than direct processing by viable H-2b macrophages. Thus, macrophages express an alternate pathway that allows MHC-I presentation of vacuolar exogenous particulate Ags, including inert synthetic particles without lipid membranes and intravacuolar bacteria. Peptides from these Ags are released from intracellular compartments to bind to surface MHC-I molecules, but peptide-MHC-I complexes also may be generated within intracellular compartments.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963555

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

1.  Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity.

Authors:  A M Doling; J D Ballard; H Shen; K M Krishna; R Ahmed; R J Collier; M N Starnbach
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.

Authors:  J T Voeten; G F Rimmelzwaan; N J Nieuwkoop; R A Fouchier; A D Osterhaus
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

4.  Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells.

Authors:  Oliver Schulz; Caetano Reis e Sousa
Journal:  Immunology       Date:  2002-10       Impact factor: 7.397

5.  The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen.

Authors:  Alexandra Mant; Fay Chinnery; Tim Elliott; Anthony P Williams
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 6.  Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.

Authors:  Madharasi V A Pichai; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2012-06-21       Impact factor: 5.742

Review 7.  Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns.

Authors:  Martin F Bachmann; Gary T Jennings
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

Review 8.  Tumor lysate-loaded biodegradable microparticles as cancer vaccines.

Authors:  Vijaya B Joshi; Sean M Geary; Brett P Gross; Amaraporn Wongrakpanich; Lyse A Norian; Aliasger K Salem
Journal:  Expert Rev Vaccines       Date:  2014-01       Impact factor: 5.217

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses.

Authors:  Paul D Hulseberg; Alla Zozulya; Hamlet H Chu; James A Triccas; Zsuzsanna Fabry; Matyas Sandor
Journal:  Immunol Lett       Date:  2009-12-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.